MVA85A Aerosol vs Intramuscular Vaccination in Adults With Latent Mycobacterium Tuberculosis (M. tb) Infection

Tuberculosis Clinical Trial

Official title:

A Phase I Trial to Compare the Safety and Immunogenicity of Candidate TB Vaccine MVA85A Administered by the Aerosol Inhaled Route and the Intramuscular Route in Healthy Adult Volunteers Who Are Latently Infected With Mycobacterium Tuberculosis

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02532036
• Other study ID #: TB040
• Status: Terminated
• Phase: Phase 1
• Start date: September 2015
• Est. completion date: October 4, 2018

Study information

• Verified date: November 2018
• Source: University of Oxford
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

TB040 is a clinical trial to investigate and compare the effects of a candidate Tuberculosis (TB) vaccine, MVA85A, administered by the aerosol inhaled route and the intramuscular route in healthy adult volunteers who are latently infected with Mycobacterium tuberculosis.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 2
• Est. completion date: October 4, 2018
• Est. primary completion date: October 4, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

Volunteers must meet all of the following criteria to enter the trial:

• Healthy adult aged 18-55 years

• Resident in or near Oxford, Birmingham or London for the duration of the trial period

• Screening IGRA positive

• Ineligible for chemoprophylaxis for latent M.tb infection, declined prophylaxis or considered low risk due to distant contact history

• Chest Computed Tomography (CT) normal; or abnormal with features consistent with primary M.tb infection but no features suggestive of active disease

• No relevant findings in medical history or on physical examination

• Allow the Investigators to discuss the individual's medical history with their General Practitioner

• Use effective contraception for the duration of the trial period (females only)

• Refrain from blood donation during the trial

• Give written informed consent

• Allow the Investigator to register volunteer details with a confidential database (The Over-volunteering Protection Service) to prevent concurrent entry into clinical trials

• Able and willing (in the Investigator's opinion) to comply with all the trial requirements

Exclusion Criteria:

Volunteers must meet none of the following criteria to enter the trial:

• Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment, or planned use during the trial period

• Prior vaccination with candidate vaccine MVA85A, candidate vaccine FP85A,any other recombinant MVA vaccine or any other candidate TB vaccine

• Administration of immunoglobulins and/or any blood products within the three months preceding the planned trial vaccination date

• Clinically significant history of skin disorder, allergy, atopy, immunodeficiency (including HIV), cancer (except BCC or CIS), cardiovascular disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder, neurological illness, psychiatric disorder, drug or alcohol abuse

• Concurrent oral or systemic steroid medication or the concurrent use of other immunosuppressive agents

• History of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the trial vaccine, sedative drugs, or any local or general anaesthetic agents

• Pregnancy, lactation or intention to become pregnant during trial period

• Any respiratory disease, including asthma

• Current smoker

• Clinically significant abnormality on screening CT thorax

• Clinically significant abnormality of pulmonary function tests

• Any nasal, pharyngeal, or laryngeal finding which precludes bronchoscopy

• Current use of any medication taken through the nasal or inhaled route including cocaine or other recreational drugs

• Clinical, radiological, or laboratory evidence of current active TB disease

• Past treatment for TB disease

• Any clinically significant abnormality of screening blood or urine tests

• Positive HBsAg, HCV or HIV antibodies

• Any other significant disease, disorder, or finding, which, in the opinion of the Investigator, may either put the volunteer at risk, affect the volunteer's ability to participate in the trial or impair interpretation of the trial data

Related Conditions & MeSH terms

• Tuberculosis

Intervention

Biological:
• Aerosol inhaled MVA85A

• Intramuscular MVA85A

• Intramuscular Saline placebo

• Aerosol inhaled Saline placebo

Locations

Country	Name	City	State
United Kingdom	NIHR Wellcome Trust Clinical Research Facility, University of Birmingham	Birmingham	West Midlands
United Kingdom	NIHR/Wellcome Trust King's Clinical Research Facility	London
United Kingdom	Royal Free Hospital NHS Foundation Trust	London
United Kingdom	Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Churchill Hospital	Oxford	Oxfordshire
United Kingdom	John Warin Ward, Churchill Hospital	Oxford	Oxfordshire

Sponsors (2)

Lead Sponsor	Collaborator
University of Oxford	University of Birmingham

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse Events (AE)	Actively and passively collected data on adverse events via diary card for 14 days after vaccination and at each visit over 6 months.	Up to Day 168
Secondary	Laboratory Markers of Immunity	Evaluation of ex-vivo ELISpot and intracellular cytokine staining in blood and bronchoalveolar lavage (BAL) samples.	Up to Day 168